Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.93
STEM's Cash to Debt is ranked lower than
82% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. STEM: 0.93 )
Ranked among companies with meaningful Cash to Debt only.
STEM' s Cash to Debt Range Over the Past 10 Years
Min: 0.69  Med: 4.81 Max: 63.74
Current: 0.93
0.69
63.74
Equity to Asset -0.39
STEM's Equity to Asset is ranked lower than
96% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. STEM: -0.39 )
Ranked among companies with meaningful Equity to Asset only.
STEM' s Equity to Asset Range Over the Past 10 Years
Min: -0.39  Med: 0.57 Max: 0.83
Current: -0.39
-0.39
0.83
F-Score: 2
Z-Score: -43.17
M-Score: 3.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -31575.63
STEM's Operating margin (%) is ranked lower than
96% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. STEM: -31575.63 )
Ranked among companies with meaningful Operating margin (%) only.
STEM' s Operating margin (%) Range Over the Past 10 Years
Min: -50159.65  Med: -3006.43 Max: -1648.1
Current: -31575.63
-50159.65
-1648.1
Net-margin (%) -30778.15
STEM's Net-margin (%) is ranked lower than
96% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. STEM: -30778.15 )
Ranked among companies with meaningful Net-margin (%) only.
STEM' s Net-margin (%) Range Over the Past 10 Years
Min: -43900  Med: -2978.47 Max: -1746.85
Current: -30778.15
-43900
-1746.85
ROE (%) -1426.69
STEM's ROE (%) is ranked lower than
99% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. STEM: -1426.69 )
Ranked among companies with meaningful ROE (%) only.
STEM' s ROE (%) Range Over the Past 10 Years
Min: -314.44  Med: -106.58 Max: -33.86
Current: -1426.69
-314.44
-33.86
ROA (%) -146.21
STEM's ROA (%) is ranked lower than
92% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. STEM: -146.21 )
Ranked among companies with meaningful ROA (%) only.
STEM' s ROA (%) Range Over the Past 10 Years
Min: -102.9  Med: -63.36 Max: -25.39
Current: -146.21
-102.9
-25.39
ROC (Joel Greenblatt) (%) -696.70
STEM's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. STEM: -696.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
STEM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1658.37  Med: -759.49 Max: -488.68
Current: -696.7
-1658.37
-488.68
Revenue Growth (3Y)(%) -42.40
STEM's Revenue Growth (3Y)(%) is ranked lower than
82% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. STEM: -42.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
STEM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -82  Med: -37.35 Max: 152.7
Current: -42.4
-82
152.7
EBITDA Growth (3Y)(%) -36.70
STEM's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. STEM: -36.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
STEM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.2  Med: -13.80 Max: 9.5
Current: -36.7
-37.2
9.5
EPS Growth (3Y)(%) -29.80
STEM's EPS Growth (3Y)(%) is ranked lower than
78% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. STEM: -29.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
STEM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.9  Med: -17.60 Max: 24
Current: -29.8
-34.9
24
» STEM's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

STEM Guru Trades in Q1 2015

Jim Simons Sold Out
» More
Q3 2015

STEM Guru Trades in Q3 2015

Jim Simons 97,500 sh (New)
» More
Q4 2015

STEM Guru Trades in Q4 2015

Jim Simons 185,900 sh (+90.67%)
» More
Q1 2016

STEM Guru Trades in Q1 2016

Jim Simons 253,900 sh (+36.58%)
» More
» Details

Insider Trades

Latest Guru Trades with STEM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:LSE:IMM, ROCO:4186, XPAR:ALQGC, ASX:AHZ, OSTO:BINV, OTCPK:RGRX » details
Traded in other countries:CY9B.Germany,
StemCells Inc is engaged in the research, development, and commercialization of cell-based stem cell therapeutics and related enabling technologies.

StemCells Inc is a Delaware Corporation incorporated in 1988. The Company is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. It is focused on cellular medicine, or the use of stem and progenitor cells as the basis for novel therapeutics and therapies, and enabling technologies for stem cell research, or the use of cells and related technologies to enable stem cell-based research and drug discovery and development. The Company's primary research and development efforts are focused on cellular medicine, where it seeks to identify and develop stem and progenitor cells as potential therapeutic agents. It currently has two therapeutic product development programs; its CNS Program, which is developing applications for HuCNS-SC cells, its proprietary human neural stem cell product candidate, and its Liver Program, which is developing applications for its proprietary human liver engrafting cells. It currently markets various proprietary cell culture products under the SC Proven brand, including iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27. The Company's primary strategy is to identify multiple types of human stem and progenitor cells with therapeutic and commercial importance, to develop techniques and processes to purify these cells for direct transplant and to expand and bank these cells, to advance these cells into clinical development and ultimately, to commercialize them as cell-based therapeutic products. The Company's research and development activities and the future manufacturing and marketing of its potential therapeutic products are, and would continue to be, subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.

Ratios

vs
industry
vs
history
P/S 75.75
STEM's P/S is ranked lower than
81% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. STEM: 75.75 )
Ranked among companies with meaningful P/S only.
STEM' s P/S Range Over the Past 10 Years
Min: 7.33  Med: 107.53 Max: 4800
Current: 75.75
7.33
4800
EV-to-EBIT -1.00
STEM's EV-to-EBIT is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. STEM: -1.00 )
Ranked among companies with meaningful EV-to-EBIT only.
STEM' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.6  Med: -2.70 Max: 0.2
Current: -1
-20.6
0.2
EV-to-EBITDA -1.04
STEM's EV-to-EBITDA is ranked lower than
99.99% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. STEM: -1.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
STEM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.2  Med: -2.90 Max: 0.2
Current: -1.04
-23.2
0.2
Current Ratio 1.62
STEM's Current Ratio is ranked lower than
81% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. STEM: 1.62 )
Ranked among companies with meaningful Current Ratio only.
STEM' s Current Ratio Range Over the Past 10 Years
Min: 1.55  Med: 5.23 Max: 21.05
Current: 1.62
1.55
21.05
Quick Ratio 1.62
STEM's Quick Ratio is ranked lower than
77% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. STEM: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
STEM' s Quick Ratio Range Over the Past 10 Years
Min: 1.55  Med: 5.23 Max: 21.05
Current: 1.62
1.55
21.05
Days Sales Outstanding 95.08
STEM's Days Sales Outstanding is ranked lower than
71% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. STEM: 95.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
STEM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.44  Med: 45.21 Max: 8100.44
Current: 95.08
16.44
8100.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.70
STEM's Price/Median PS Value is ranked higher than
69% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. STEM: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
STEM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.78 Max: 39.94
Current: 0.7
0.01
39.94
Earnings Yield (Greenblatt) (%) -101.10
STEM's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. STEM: -101.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
STEM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -101.1  Med: 653.30 Max: 3143.6
Current: -101.1
-101.1
3143.6

More Statistics

Revenue (TTM) (Mil) $0.12
EPS (TTM) $ -14.90
Beta0.08
Short Percentage of Float8.88%
52-Week Range $2.45 - 9.19
Shares Outstanding (Mil)11.70

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 0 0 0
EPS ($) -2.88 -1.68 -0.48
EPS without NRI ($) -2.88 -1.68 -0.48
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for STEM

Headlines

Articles On GuruFocus.com
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
StemCells Inc. Reports Operating Results (10-Q) Nov 03 2010 
StemCells Inc. Reports Operating Results (10-Q) May 04 2010 
StemCells Inc. Reports Operating Results (10-Q) Nov 05 2009 
StemCells Inc. Reports Operating Results (10-Q) Aug 10 2009 
The Next Boom Emerges Nov 23 2008 

More From Other Websites
StemCells, Inc. :STEM-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 May 26 2016
STEMCELLS INC Files SEC form 8-K, Other Events May 20 2016
STEMCELLS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... May 19 2016
STEMCELLS INC Financials May 19 2016
STEMCELLS INC Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to... May 10 2016
StemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway Study May 10 2016
StemCells, Inc. Announces 1-for-12 Reverse Stock Split May 06 2016
STEMCELLS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year May 03 2016
StemCells, Inc. to Participate in the 3rd Annual Growth Capital Expo MicroCap Investor Conference in... Apr 27 2016
StemCells, Inc. to Participate in the 3rd Annual Growth Capital Expo MicroCap Investor Conference in... Apr 27 2016
Top Penny Stocks: Four Trending Small Cap Stocks That Require Your Attention on April 18th 2016 Apr 18 2016
StemCells, Inc. Presents Interim Results from its Phase II Pathway Study in Chronic Cervical Spinal... Apr 18 2016
StemCells, Inc. Presents Interim Results from its Phase II Pathway Study in Chronic Cervical Spinal... Apr 18 2016
StemCells, Inc., Pathway™ Study in Cervical Spinal Cord Injury Featured in The Downey Patriot Mar 30 2016
Edited Transcript of STEM earnings conference call or presentation 24-Mar-16 12:00pm GMT Mar 28 2016
[$$] StemCells Set to Regenerate Itself Mar 28 2016
StemCells Inc Earnings Call scheduled for 8:00 am ET today Mar 24 2016
STEMCELLS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 23 2016
StemCells, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business... Mar 23 2016
StemCells, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business... Mar 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)